Pilot Study of Ranibizumab (Lucentis) for Neurofibromas Associated With Neurofibromatosis 1

Trial Profile

Pilot Study of Ranibizumab (Lucentis) for Neurofibromas Associated With Neurofibromatosis 1

Completed
Phase of Trial: Phase 0

Latest Information Update: 11 Jul 2016

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Neurofibroma
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 13 Aug 2015 The recruitment status of this study is unknown because the information has not been verified recently (Verified on March 2013 ). So kept previous status as active not recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top